HYMPAVZI’s approval is based on Phase 3 study results demonstrating substantial bleed reduction compared to routine prophylaxis
Expansion includes a new 5-story, 136k sq. ft. multipurpose building in Sejong
The new bioeconomy policy rolled out by the Modi government is set to place India as a global leader in the years to come
Collaboration with KNAUER to streamline and improve the scale-up of LNP formulations
Pharmaceuticals and Consumer Health report higher sales (Fx & portfolio adj.) and lower earnings
Facility in The Woodlands, Texas to produce critical starting material for cell and gene therapy, DNA/RNA-based, and recombinant protein therapeutics in Q1/2025
The new facility will accelerate the biotech and pharmaceutical industry's development by manufacturing vaccines, cell and gene therapies, and protein-based therapies
Acquisition will advance Merck’s integrated offering for viral vector manufacturing
Wacker Biotech US, a wholly owned subsidiary of Wacker Chemie AG, specializes in the microbial production of pDNA
Cellectis is also eligible to receive an investigational new drug (IND) option fee and development
Subscribe To Our Newsletter & Stay Updated
